Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 278

1.

The double-blind variable placebo lead-in period: results from two antidepressant clinical trials.

Faries DE, Heiligenstein JH, Tollefson GD, Potter WZ.

J Clin Psychopharmacol. 2001 Dec;21(6):561-8. Review.

PMID:
11763002
2.

Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.

Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.

Curr Med Res Opin. 2007 Jun;23(6):1303-18. Epub 2007 Apr 27.

PMID:
17559729
3.

Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.

Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C; BOTOX CDH Study Group.

Headache. 2005 Apr;45(4):293-307.

PMID:
15836565
5.

Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder.

Delgado PL, Brannan SK, Mallinckrodt CH, Tran PV, McNamara RK, Wang F, Watkin JG, Detke MJ.

J Clin Psychiatry. 2005 Jun;66(6):686-92.

PMID:
15960560
6.

Duloxetine: a review of its use in the treatment of generalized anxiety disorder.

Carter NJ, McCormack PL.

CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. Review.

PMID:
19480470
7.

Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.

Khan A, Bose A, Alexopoulos GS, Gommoll C, Li D, Gandhi C.

Clin Drug Investig. 2007;27(7):481-92.

PMID:
17563128
8.

Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression.

Leuchter AF, Morgan M, Cook IA, Dunkin J, Abrams M, Witte E.

Psychopharmacology (Berl). 2004 Dec;177(1-2):15-22. Epub 2004 Jul 14.

PMID:
15252704
9.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
10.

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.

J Clin Psychiatry. 2004 Oct;65(10):1356-64.

PMID:
15491239
11.

A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.

Patkar AA, Masand PS, Pae CU, Peindl K, Hooper-Wood C, Mannelli P, Ciccone P.

J Clin Psychopharmacol. 2006 Dec;26(6):653-6.

PMID:
17110825
12.

The impact of restrictive entry criterion during the placebo lead-in period.

Landin R, DeBrota DJ, DeVries TA, Potter WZ, Demitrack MA.

Biometrics. 2000 Mar;56(1):271-8.

PMID:
10783806
13.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
14.

[Use of antidepressant drugs in schizophrenic patients with depression].

Micallef J, Fakra E, Blin O.

Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. Review. French.

PMID:
16910628
15.

Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.

Jahn H, Schick M, Kiefer F, Kellner M, Yassouridis A, Wiedemann K.

Arch Gen Psychiatry. 2004 Dec;61(12):1235-44.

PMID:
15583115
16.

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW.

J Clin Psychopharmacol. 2008 Dec;28(6):631-7. doi: 10.1097/JCP.0b013e31818a6cea.

PMID:
19011431
17.

Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.

Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF.

J Psychiatr Res. 2005 Jan;39(1):43-53.

PMID:
15504423
18.

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.

Nierenberg AA, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, Tollefson GD, Wohlreich MM.

Curr Med Res Opin. 2007 Feb;23(2):401-16.

PMID:
17288694
19.

Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study.

DeBattista C, Doghramji K, Menza MA, Rosenthal MH, Fieve RR; Modafinil in Depression Study Group.

J Clin Psychiatry. 2003 Sep;64(9):1057-64.

PMID:
14628981
20.

Supplemental Content

Support Center